Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer

* A cohort of three patients will be treated at each dose level for one cycle (28 days per cycle). * Treatment will be continued if no DLTs are recorded, and three patients will be treated at the next higher dose level. * If a patient of the cohort develops a DLT, however, another cohort of three patients will be treated for 1 cycle. * If more DLTs do not develop, dose escalation continues. * If more than one of three patients develop a DLT at any dose level, another cohort of three patients will be treated at the next lower dose level. * If no DLTs are recorded in any of the cohorts, the number of patients per cohort will be increased from 3 to 6. * Up to 12 patients will be enrolled at the MTD. * Therefore, the phase II dose for this combined therapy will be defined as the highest dose level at which six patients were treated and less than three DLTs developed.